Expert Opinion on Emerging Drugs

SJR Rank #5,701H-index: 59SJR: 0.908Best quartile: Q2
Journal website: aims, scope and author guidelines
Publisher

Taylor and Francis Ltd.

Country

United Kingdom

Type

journal

SJR by Edition

2022202500.250.50.751

Subject Categories

  • PharmacologyQ2
  • Pharmacology (medical)Q2

Areas: Medicine · Pharmacology, Toxicology and Pharmaceutics

Most published research topics

Asthma and respiratory diseasesRetinal Diseases and TreatmentsCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsCAR-T cell therapy researchPsoriasis: Treatment and PathogenesisHER2/EGFR in Cancer ResearchRheumatoid Arthritis Research and TherapiesChronic Lymphocytic Leukemia ResearchPhosphodiesterase function and regulation

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs0255075100

Documents per Year

2022202509182736

Detailed Information

ISSN

1472-8214, 1744-7623

SJR Best Quartile

Q2

Region

Western Europe

Citations per Document (2 years)

3.44

References per Document

76.09

Coverage

2000-2025

Scope

Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.

Metrics from SCImago Journal Rank 2025. View on SCImago